Please ensure Javascript is enabled for purposes of website accessibility

This Is How Amgen Avoided a Catastrophic Q1 Update

By Cory Renauer - Apr 29, 2021 at 6:51AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Despite disappointing results that missed expectations, progress with an important new cancer drug saved the day.

After U.S. stock markets closed on Tuesday, Amgen (AMGN 0.93%) disappointed investors by missing analyst expectations on the top and bottom lines. First-quarter sales of the company's drugs have been impacted by the COVID-19 pandemic, as repeated outbreaks make it harder for patients with other conditions to seek treatment.

The situation is bad enough that the company lowered adjusted earnings expectations for 2021 to a range of between $9.11 and $10.71 per share, from a previous prediction that ranged between $12.12 and $13.17 per share.

A scientist in white coat and surgicsl mask looks into a microscope.

Image source: Getty Images.

Despite Amgen reporting its ugliest quarter in years, its shares haven't collapsed. Here's why progress with a potential new cancer drug is helping investors stay focused on the long term.

Looking forward to Lumakras

Last December, Amgen submitted an application to the Food and Drug Administration for a potential new lung cancer drug with blockbuster potential. Lumakras, formerly sotorasib, is the first in a new class of treatments -- which target tumors driven by out-of-control KRAS proteins -- to get this far.

Roughly 13% of Americans diagnosed with non-small cell lung cancer have aggressive tumors that harbor the specific KRAS mutation Lumakras is designed to treat. If approved ahead of rival treatments from Mirati Therapeutics (MRTX 6.03%), Boehringer Ingelheim, and others, annual Lumakras sales could pass $5 billion annually by 2025.

Further down the road, Lumakras could become Amgen's top-selling drug. That's because tumors that originate in the lung aren't the only ones known to harbor KRAS mutations. Lumakras' target has also been found in tumors that originate in the pancreas and colon. Clinical trials that could expand this drug's addressable patient population are well underway.

Approval around the corner?

The FDA's ongoing priority review is expected to wrap up later this summer, but an approval announcement for Lumakras could come much sooner. Less than a day after announcing disappointing first-quarter earnings results, Amgen told investors it would start a post-marketing study with Lumakras to meet a post-marketing requirement proposed by the FDA. This is the sort of trial that companies run when the agency approves a new cancer drug before there's been enough time to produce long-term outcome data.

In trials supporting Lumakras' application for accelerated approval, it shrank tumors for 37% of advanced-stage lung cancer patients who had already relapsed after previous treatments. Around one-fifth of participants experienced serious side effects, but it doesn't look like safety issues are going to prevent the FDA from making this new drug available to lung cancer patients who have already exhausted their treatment options.

Further ahead

Lumakras is the most advanced KRAS-inhibitor in development at the moment, but it isn't the only one. Adagrasib, from Mirati Therapeutics, shrank tumors for 45% of lung cancer patients in a relatively small clinical trial.

Mirati Therapeutics has begun a phase 3 lung cancer trial comparing adagrasib to chemotherapy, but the much smaller company has fewer resources to lean on. Going into 2022, Amgen will most likely have the only approved KRAS inhibitor.

A buy now?

Amgen's shares slid about 7% following its disappointing first-quarter report. The pressure on the stock price, though, has driven its dividend yield up to an even 3% at this writing.

Over the past five years, Amgen has raised its quarterly payout 76%, and the company remains committed to returning profits to shareholders. Despite steady payout raises, the company used just 24% of the free cash flow generated over the past year to make dividend payments, so there's plenty of room to bump it higher.

Amgen is already a giant biopharmaceutical company, so it isn't going to grow by leaps and bounds. With its relatively steady profits, though, you aren't going to lose money holding on to shares of this diversified drugmaker.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Amgen Inc. Stock Quote
Amgen Inc.
AMGN
$245.55 (0.93%) $2.25
Mirati Therapeutics, Inc. Stock Quote
Mirati Therapeutics, Inc.
MRTX
$71.18 (6.03%) $4.05

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/04/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.